Prof Baigent discusses the key areas of uncertainty about SGLT2 inhibitors in patients with CKD and what ongoing trials will contribute.
In the PIONEER 1 and 3 phase 3a trials, oral semaglutide reduced HbA1c and body weight in T2DM patients compared to placebo or sitagliptin.
In a study of middle-aged female twins, the composition of the gut microbiome was strongly correlated with arterial stiffness, independently of traditional risk factors.
In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.
A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.
In type 2 diabetes patients at high CV risk and chronic kidney disease, the SGLT2 inhibitor canagliflozin consistently improved CV and renal outcomes across different levels of kidney function.
In two prospective population cohorts, the increased CVD risk in individuals with high Lp(a) levels was reduced when LDL-c levels were <2.5 mmol/L.
In a phase 2a study, MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.
Lp(a) concentrations have to be decreased by approximately 100 mg/dL in order to achieve clinically meaningful reductions in the risk of CHD, as shown by Mendelian randomization analysis.
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.